Pharma Dealmakers, Sidelined in Pandemic, Are Ready for Comeback
Bankers and executives flooded an old San Francisco hotel this past January for the drug industry’s premier event for networking, hobnobbing and doing deals.
Six months later, in the middle of the Covid-19 pandemic, the JP Morgan Annual Healthcare Conference, with its crowded panels and presentations, finger food and seas of suits, feels like a distant memory. But that doesn’t mean mergers are dead.
